Effects of a gluten-free diet on gut microbiota and immune function in healthy adult human subjects

Giada De Palma, Inmaculada Nadal, Maria Carmen Collado and Yolanda Sanz*

Microbial Ecophysiology and Nutrition Group, Institute of Agrochemistry and Food Technology (IATA), Spanish National Research Council (CSIC), PO Box 73, 46100 Burjassot, Valencia, Spain

Diet influences the composition of the gut microbiota and host's health, particularly in patients suffering from food-related diseases. Coeliac disease (CD) is a permanent intolerance to cereal gluten proteins and the only therapy for the patients is to adhere to a life-long gluten-free diet (GFD). In the present preliminary study, the effects of a GFD on the composition and immune function of the gut microbiota were analysed in ten healthy subjects (mean age 30·3 years) over 1 month. Faecal microbiota was analysed by fluorescence *in situ* hybridisation (FISH) and quantitative PCR (qPCR). The ability of faecal bacteria to stimulate cytokine production by peripheral blood mononuclear cells (PBMC) was determined by ELISA. No significant differences in dietary intake were found before and after the GFD except for reductions ($P=0.001$) in polysaccharides. *Bifidobacterium*, *Clostridium lituseburense* and *Faecalibacterium prausnitzii* proportions decreased ($P=0.007$, $P=0.031$ and $P=0.009$, respectively) as a result of the GFD analysed by FISH. *Bifidobacterium*, *Lactobacillus* and *Bifidobacterium longum* counts decreased ($P=0.020$, $P=0.001$ and $P=0.017$, respectively), while *Enterobacteriaceae* and *Escherichia coli* counts increased ($P=0.005$ and $P=0.003$) after the GFD assessed by qPCR. TNF-α, interferon-γ, IL-10 and IL-8 production by PBMC stimulated with faecal samples was also reduced ($P=0.021$, $P=0.037$, $P=0.002$ and $P=0.007$, respectively) after the diet. Therefore, the GFD led to reductions in beneficial gut bacteria populations and the ability of faecal samples to stimulate the host's immunity. Thus, the GFD may constitute an environmental variable to be considered in treated CD patients for its possible effects on gut health.

Intestinal microbiota: Gluten-free diet: Coeliac disease: Immunity

Diet influences the composition and function of the gut microbiota and thereby the host's health, particularly in patients suffering from food-related diseases. Coeliac disease (CD) is an inflammatory disorder of the small intestine caused by a permanent intolerance to gluten proteins in predisposed individuals. In these patients, gluten peptides trigger an abnormal immune response that causes the typical CD tissue lesion characterised by villous atrophy, crypt hyperplasia, and increased numbers of intra-epithelial and lamina propria lymphocytes[1,2]. CD enteropathy is sustained by a T-helper (Th)1 immune response with production of pro-inflammatory cytokines (for example, interferon (IFN)-γ), as well as by an innate immune response mediated by IL-15 that activates intra-epithelial lymphocytes and epithelial cell killing[3]. Increased production of pro-inflammatory cytokines by cells of the innate immune system (monocytes, macrophages and dendritic cells) is also thought to mediate the recruitment of lymphocytes into the lamina propria and epithelium, thus contributing to the disease[4]. The treatment with a gluten-free diet (GFD) usually leads to normalisation of mucosal histology and remission of clinical symptoms. Nevertheless, compliance with this dietary therapy is very complex and patients often suffer from higher health risks and nutritional deficiencies[5,6]. The composition and metabolic activity of the intestinal microbiota is currently thought to be involved in a number of chronic inflammatory disorders. Most recent studies indicate that CD patients untreated and treated with a GFD have unbalanced microbiota that can play a pathogenic role or constitute a risk factor for this disorder[7,8]. Nevertheless, part of the detected microbial changes could be due not only to the underlying disease but also to the dietary intervention by a GFD in treated CD patients. A GFD has also been tested as dietary treatment for autism[9]. However, the possible effect of a GFD in the gut ecosystem remains largely unknown.

The objective of the present study was to analyse the impact of a GFD on the composition and immune function of the microbiota in healthy subjects to gain further insights on interactions between diet and gut microbes, as well as on

the possible effects of this therapy on gut health and quality of life of CD patients.

Experimental methods

Subjects

Ten volunteers (eight women and two men; mean age 30·3 years; range 23–40 years) were included in the study. All participants included in the present study had no history of digestive pathology or signs of malnutrition. None of the volunteers had been treated with antibiotics at least within the 2 months before the faecal sampling. Informed consent was obtained from the subjects, and the study was approved by the local ethics committee.

Dietary intervention and assessments

Subjects were submitted to a GFD by replacing gluten-containing foods by equivalent ones certified as gluten-free (20 parts per million maximum gluten content) by the Spanish Federation of Coeliac Association (FACE) over a 1-month period. Food diary records were kept for 72 h (2 weekdays and 1 weekend day) both before the start of the intervention and after 1 month to monitor dietary changes. At the front of the diary, detailed information on how to record food and beverages consumed using common household measures was provided. When completing the food diary records, subjects were instructed to record everything they ate or drank. Food diary records were returned to the dietitian as soon as possible after completion when they were reviewed, and analysed for energy, water and macronutrient contents based on the CESNID food composition database of Spanish foods[10].

Faecal sampling

Faecal samples from each adult volunteer were collected before and after following the GFD and processed as described elsewhere in duplicate[7,11]. Briefly, 2 g (wet weight) were 10-fold diluted in PBS (130 mM-sodium chloride, 10 mM-sodium phosphate, pH 7·2) and homogenised for 5 min in a Lab Blender 400 stomacher (Seward Medical, London, UK). The homogenised samples were subjected to a low-spin centrifugation (2000 rpm, 2 min) to remove large particulate material, and samples of the obtained supernatant fractions were used for either DNA extraction or hybridisation. Before hybridisation, one volume of the supernatant fraction was mixed with three volumes of fresh 4 % paraformaldehyde, fixed at 4°C overnight, and stored in 50 % ethanol–PBS at −80°C until use for hybridisation[7,11]. DNA extractions were done by using the QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany) following the manufacturer's instructions.

Fluorescence in situ hybridisation and flow cytometry detection

Enumeration of bacteria present in faecal samples was carried by fluorescence in situ hybridisation (FISH) using 16S rRNA-targeted oligonucleotide probes (MOLBIOL,

Berlin, Germany), as previously described[7,11]. The following probes were used: EUB 338 for the detection of total bacteria[12]; Ato291 for Atopobium group[13]; Bif164 for Bifidobacterium genus[14]; Lab158 for Lactobacillus and other lactic acid bacteria[15]; Bac303 for Bacteroides–Prevotella group[16]; Ecol1513 for Escherichia coli[17]; Erec0482 for Eubacterium rectale–Clostridium coccoides group[18]; CHis159 for C. histolyticum group[13]; CLis135 for C. lituseburense group[19]; Fprau645 for Faecalibacterium prausnitzii[20]. Cells were enumerated by combining in the same hybridisation tube one group-specific fluorescein isothiocyanate probe with the EUB 338-Cy3 probe. The proportion of group cells was corrected by eliminating background fluorescence, which was measured using the negative control NON 338 probe[7,21]. Fixed cells were incubated in the hybridisation solution (10 mM-2-amino-2-hydroxymethyl-propane-1,3-diol-HCl, 0·9 M-NaCl, pH 8·0, and 10 % SDS) containing 4 ng/μl of each fluorescent probe at appropriate temperatures overnight, washed and re-suspended in PBS solution for flow cytometric analysis[7,11].

Flow cytometry detections were performed using an EPICS® XL-MCL flow cytometer (Beckman Coulter, Miami, FL, USA) as previously described[7,22]. This instrument is equipped with two light scatter detectors that measure forward and side scatter and fluorescence detectors that detect appropriately filtered light at green (FL1; 525 nm) and red-orange (FL3; 620 nm) wavelengths. The event rate was kept at the lowest setting (200–300 events per s) to avoid cell coincidence. A total of 15 000 events were recorded in a list mode file and analysed with System II V.3 software (Beckman Coulter). The proportion of each bacterial group was expressed as a ratio of cells hybridising with the fluorescein isothiocyanate-labelled specific probe to cells hybridising with the universal EUB 338-Cy3 probe[7,22].

Quantitative real-time polymerase chain reaction analysis

Quantitative PCR (qPCR) was used to characterise the composition of the faecal microbiota by the use of specific primers targeting different intestinal bacterial groups as described elsewhere[23,24]. PCR amplification and detection were performed with an ABI PRISM 7000-PCR sequence detection system (Applied Biosystems, Warrington, Cheshire, UK). Each reaction mixture of 25 μl was composed of SYBR® Green PCR Master Mix (SuperArray Bioscience Corporation, Frederick, MD, USA), 1 μl of each of the specific primers at a concentration of 0·25 μM and 1 μl of template DNA. The bacterial concentration from each sample was calculated by comparing the Ct (cycle threshold) values obtained from standard curves. Standard curves were created using serial 10-fold dilution of pure culture DNA corresponding to 10^2 to 10^9 cells as determined by microscopy counts using 4′,6-diamidino-2-phenylindole.

Isolation and stimulation of peripheral blood mononuclear cells

Peripheral blood mononuclear cells (PBMC) were isolated from heparinised peripheral blood of four healthy volunteers (aged 26–28 years) as previously described[25]. Briefly, PBMC were isolated by centrifugation over a Ficoll density

gradient (Amersham Biosciences, Piscataway, NJ, USA) and adjusted to 1×10^6 cells/ml in Roswell Park Memorial Institute (RPMI) 1640 (Cambrex, New York, NY, USA), supplemented with 10 % fetal bovine serum (Gibco, Barcelona, Spain), 2 mM-L-glutamine, streptomycin (100 μg/ml) and penicillin (100 U/ml) (Sigma, St Louis, MO, USA). PBMC were incubated in twenty-four-well flat-bottomed polystyrene microtitre plates (Corning, Madrid, Spain) and incubated at 37°C under 5 % CO_2. Faecal samples, 30 μl, of each subject before and after following the GFD were used to stimulate PBMC for 24 h. Purified lipopolysaccharide (LPS) from *Escherichia coli* O111:B4 (Sigma) was used at a concentration of 1 μg/ml as a positive control. Non-stimulated PBMC were also evaluated as controls of basal cytokine production. All reagents were tested by the E-toxate test for LPS (Sigma) and shown to be below the limit of detection (2 pg/ml). Every sample used as stimulant was assayed in duplicate. Cell-culture supernatant fractions were collected by centrifugation, fractionated in samples, and stored at −20°C until cytokines were analysed.

Cytokine assays

Cytokine concentrations of supernatant fractions were measured by ELISA. The pro-inflammatory cytokines TNF-α and IFN-γ and the regulatory cytokine IL-10 were analysed by using the Ready SET Go! Kit (eBioscience, San Diego, CA, USA), and the chemokine IL-8 by using a Diaclone ELISA commercial kit (Diaclone, Madrid, Spain), according to the manufacturers' instructions. The sensitivity of assays for each cytokine was as follows: 4 pg/ml for TNF-α and IFN-γ, 2 pg/ml for IL-10 and < 25 pg/ml for IL-8.

Statistical analyses

Statistical analyses were done using SPSS 11.0 software (SPSS Inc., Chicago, IL, USA). Dietary composition (mean values and standard deviations) was calculated for crude (unadjusted) nutrients from the 72 h dietary registers and data were averaged for the analysis. Dietary variables were submitted to log-transformation and mean comparisons before and after the intervention were determined by applying the Student's *t* test. Microbial data are expressed as medians with interquartile ranges (IQR) and the differences in bacterial counts before and after GFD were determined by applying the Mann–Whitney *U* test. Results of cytokine production are expressed as means with standard deviations and differences were determined by applying the Student's *t* test. In every case, *P* values < 0·05 were considered statistically significant.

Results and discussion

Gluten-free diet influences the composition of the intestinal microbiota in healthy subjects

A preliminary study was carried out to establish the effects of a GFD on the composition of the intestinal microbiota and to gain insights into the possible relationship of this dietary therapy with gut health. The adult human subjects included in the study, 80 % female (eight out of ten) and 20 % male (two out of ten), maintained a good health status during the

intervention, and followed a conventional diet without any restriction except for gluten-containing products. Dietary data before and after the intervention are shown in Table 1. No significant differences in dietary intake were found in energy and macronutrients as a result of the GFD except for significant reductions (*P*=0·001) in polysaccharide intake. Previous studies on the nutritional quality of the GFD also indicated that it is associated with reductions in the intake of polysaccharides together with energy compared with the standard gluten-containing diet of healthy individuals, according to the present results[26]. The composition of the faecal microbiota under the effects of the GFD determined by FISH is shown in Table 2. Individual baseline variability of bacterial populations expressed as median of differences in proportions of bacterial cells hybridising with group-specific probes related to total bacteria hybridising with EUB probe 338 was as follows: 2·38 (IQR 1·01−5·30) for *Atopobium* group; 1·86 (IQR 1·42−3·10) for *Bifidobacterium*; 1·54 (IQR 1·09−2·13) for *Lactobacillus* group; 2·16 (IQR 0·86−3·26) for *Bacteroides−Prevotella*; 1·29 (IQR 0·84−1·47) for *Escherichia coli*; 6·54 (IQR 0·21−10·41) for *Eubacterium rectale−C. coccoides*; 1·04 (IQR 0·41−2·48) for *C. histolyticum*; 1·63 (IQR 0·59−3·61) for *C. lituseburense*; 6·65 (IQR 0·62−6·72) for *F. prausnitzii*. *Bifidobacterium*, *C. lituseburense* and *F. prausnitzii* proportions decreased significantly (*P*=0·007, *P*=0·031 and *P*=0·009, respectively) as a result of the GFD (Table 2). *Lactobacillus* group proportions were also almost significantly reduced (*P*=0·058) after the GFD (Table 2).

Table 1. Daily energy and nutrient intake before and after the gluten-free diet (GFD) intervention

(Mean values and standard deviations)

Diet composition	Subjects before GFD (*n* 10)		Subjects under GFD (*n* 10)	
	Mean	SD	Mean	SD
Energy				
kJ	7759·68	1446·91	7464·51	1263·28
kcal	1854·61	345·82	1784·06	301·93
Water (g)	2454·56	533·35	2764·96	464·18
Protein (g)	72·99	15·69	68·48	13·19
Energy from protein (%)	15·74	3·38	15·35	2·96
Fat (g)	78·69	21·12	71·95	19·00
Energy from fat (%)	38·19	10·25	36·30	9·58
Saturated fat (g)	23·21	11·17	22·42	6·55
Energy from saturated fat (%)	11·26	5·42	11·31	3·30
MUFA (g)	29·97	8·30	28·79	8·41
Energy from MUFA (%)	14·54	4·03	14·52	4·24
PUFA (g)	11·58	5·59	9·43	3·93
Energy from PUFA (%)	5·62	2·71	4·76	1·98
Cholesterol (mg)	262·36	181·37	266·76	115·07
CH (g)	212·41	55·42	218·87	69·05
Energy from CH (%)	45·81	11·95	49·07	15·48
Simple CH (g)	74·30	37·72	72·03	28·05
Energy from simple CH (%)	16·02	8·14	16·15	6·29
Polysaccharides (g)	116·63	51·62	62·95*	33·12
Energy from complex CH (%)	25·15	11·13	14·11	7·43
Dietary fibre (g)	19·52	10·78	17·56	9·13

CH, carbohydrates.

* Mean value was significantly different from that before the GFD (*P*<0·05; Student's *t* test).

Table 2. Composition of the faecal microbiota of healthy adults before and after following a gluten-free diet (GFD) analysed by fluorescent *in situ* hybridisation (FISH) and flow cytometry detection (FCM)†

(Medians and interquartile ranges (IQR))

Microbial group	Adults under standard diet (*n* 10)		Adults under GFD diet (*n* 10)		
	Median	IQR	Median	IQR	*P*
Atopobium	6·09	3·46−9·60	3·35	1·8−4·87	0·122
Bifidobacterium	11·14	7·64−16·70	5·12	3·92−8·51	0·007*
Lactobacillus−Enteroccoccus	2·58	1·34−3·50	0·78	0·56−2·66	0·058
Bacteroides−Prevotella	5·99	3·21−9·49	2·05	1·54−6·61	0·102
Escherichia coli	6·08	3·46−10·56	8·42	4·21−12·21	0·501
Eubacterium rectale−Clostridium coccoides	6·56	4·19−20·15	4·52	1·81−9·77	0·122
Clostridium histolyticum	7·87	3·99−12·01	6·93	3·72−10·47	0·753
Clostridium lituseburense	5·39	3·44−8·02	3·43	1·41−4·21	0·031*
Faecalibacterium prausnitzii	13·77	8·37−17·98	5·08	4·41−7·20	0·009*

* $P < 0.05$ (Mann−Whitney *U* test).
† Data are group-specific bacterial proportions related to total population detected with the EUB universal probe as determined by FCM−FISH.

Bacteroides−Prevotella, *Eubacterium rectale−C. coccoides* and *C. histolyticum* group proportions were slightly reduced, while those of *Escherichia coli* were increased after the GFD but not significantly (Table 2). Total counts determined by FISH using 4′,6-diamidino-2-phenylindole also showed significant reductions after the GFD from 10·25 to 9·98 log cells/g faeces ($P = 0.030$). The composition of the faecal microbiota analysed by qPCR is shown in Table 3. Individual baseline variability of bacterial populations expressed as median of differences in log cells per g faeces was as follows: 0·37 (IQR 0·17−0·65) for *Bifidobacterium*; 1·50 (IQR 0·21−1·68) for *Bacteroides*; 0·40 (IQR 0·08−0·82) for *C. coccoides*; 0·27 (IQR 0·13−1·05) for *C. leptum*; 0·27 (IQR 0·33−0·37) for *C. histolyticum*; 0·87 (IQR 0·20−1·13) for *Lactobacillus*; 0·48 (IQR 0·24−1·18) for *Escherichia coli*; 0·80 (IQR 0·15−1·37) for *Enterobacteriaceae*. The counts of *Bifidobacterium* and *Lactobacillus* groups decreased significantly after the GFD ($P = 0.020$ and $P = 0.001$, respectively), while those of *Escherichia coli* ($P = 0.003$) and

total *Enterobacteriaceae* ($P < 0.005$) significantly increased as a result of the GFD, following a similar trend as that detected by FISH. Total counts were also reduced after the GFD when determined by qPCR from 9·85 to 9·71 log cells/g faeces ($P = 0.089$), following the same trend as by FISH quantification. Therefore, introduction of a GFD implied a reduction in bacterial populations generally regarded as beneficial for human health such as *Bifidobacterium* and *Lactobacillus*, and an increase in those of opportunistic pathogens such as *Escherichia coli* and total *Enterobacteriaceae*. These changes could be related to reductions in polysaccharide intake, since these dietary compounds usually reach the distal part of the colon partially undigested, and constitute one of the main energy sources for beneficial components of the gut microbiota[27]. In addition, reductions in *Bifidobacterium* and *Lactobacillus* populations relative to Gram-negative bacteria (*Bacteroides* and *Escherichia coli*) were previously detected in untreated CD children and particularly in treated CD patients with a GFD[7]. These findings

Table 3. Composition of the faecal microbiota of healthy adults before and after following a gluten-free diet (GFD) analysed by quantitative PCR†

(Medians and interquartile ranges (IQR))

Microbial group	Adults under standard diet (*n* 10)			Adults under GFD diet (*n* 10)			
	Prevalence‡	Median	IQR	Prevalence‡	Median	IQR	*P*
Bifidobacterium	10	8·85	7·84−9·24	10	7·79	7·43−8·45	0·020*
Bacteroides	10	8·61	8·03−9·20	10	8·21	7·25−9·21	0·450
Clostridium coccoides	10	9·44	8·51−10·11	10	9·52	8·73−9·92	0·983
Clostridium leptum	10	9·54	9·18−10·31	10	10·11	9·81−10·52	0·141
Clostridium histolyticum	10	5·70	5·17−6·34	10	6·48	5·13−6·59	0·223
Lactobacillus	10	7·73	7·10−7·98	10	7·00	6·25−7·64	0·001*
Escherichia coli	10	6·29	5·67−6·77	10	7·40	6·83−7·96	0·003*
Enterobacteriaceae	10	6·64	5·86−7·99	10	8·16	7·41−8·42	0·005*
Bifidobacterium species							
Bifidobacterium longum	10	7·73	7·61−8·62	10	7·32	6·54−7·79	0·017*
Bifidobacterium breve	8	4·72	4·47−5·94	8	5·00	4·60−5·56	0·757
Bifidobacterium bifidum	10	6·75	6·73−6·76	10	6·75	6·75−6·85	0·208
Bifidobacterium adolescentis	7	5·71	4·83−8·65	8	6·73	5·39−7·80	0·975
Bifidobacterium catenulatum	10	6·81	6·05−8·4	10	6·66	5·88−8·13	0·538
Bifidobacterium angulatum	5	5·00	4·95−5·24	5	5·35	5·06−5·42	0·038*
Bifidobacterium lactis	6	5·82	5·21−6·58	5	4·89	4·62−5·63	0·201

* $P < 0.05$ (Mann−Whitney *U* test).
† Data are log cell number/g faeces.
‡ Prevalence reflects the number of positive amplifications from total samples analysed by quantitative PCR.

indicate that this dietary therapy may contribute to reduce beneficial bacterial group counts and increase enterobacterial counts, which are microbial features associated with the active phase of CD[7,28] and, therefore, it would not favour completely the normalisation of the gut ecosystem in treated CD patients. The relative proportion of *F. prausnitzii* was also significantly reduced after the GFD in healthy adults following a similar trend as that detected in untreated or treated CD patients compared with controls[7]. A depletion of *F. prausnitzii* population in faecal mucus of active Crohn's disease patients has also been detected, leading to an inverse relationship between the abundance of this population and inflammatory bowel disorders[29]. *Bifidobacterium* species composition was also analysed under the effect of the GFD by qPCR (Table 3). Individual baseline variability of bacterial populations expressed as median of differences in log cells/g faeces was as follows: 0·71 (IQR 0·08–1·33) for *Bifidobacterium longum*; 0·68 (IQR 0·07–1·03) for *B. breve*; 1·16 (IQR 0·77–1·07) for *B. bifidum*; 0·86 (IQR 0·17–1·29) for *B. adolescentis*; 1·21 (IQR 0·63–1·72) for *B. catenulatum*; 0·30 (IQR 0·002–0·45) for *B. angulatum*; 0·35 (IQR 0·19–0·82) for *B. lactis*. The counts of *B. angulatum* were significantly increased ($P=0.038$) after the GFD, while those of *B. longum* decreased ($P=0.017$), indicating that this species contributed to the reduction detected in total *Bifidobacterium* population (Table 3).

The genome sequence of *B. longum* subsp. *longum* showed that more than 8 % of the annotated genes were involved in carbohydrate and polysaccharide metabolism[30], which could explain the reduction of their levels after the GFD, parallel with a reduction in polysaccharide intake.

Gluten-free diet influences immunostimulatory activity of the intestinal microbiota

Changes in cytokine production patterns stimulated by faecal samples of healthy individuals after and before the GFD are shown in Fig. 1. Immunostimulatory properties of the colonic content of these individuals, representing an altered microbiota, were remarkably reduced after following a GFD, inducing a significantly lower production of the pro-inflammatory cytokines TNF-α ($P=0.021$) and IFN-γ ($P=0.037$) and the chemokine IL-8 ($P=0.007$). Thus, a GFD could contribute to reduce the pro-inflammatory signals in the gut by introducing modifications in the microbiota structure. In addition, the faecal samples of individuals under a GFD induced significantly lower production of the anti-inflammatory cytokine IL-10 ($P=0.002$) than those of individuals on a standard gluten-containing diet. IL-10 inhibits the production of pro-inflammatory and Th1 cytokines such as


Fig. 1. Cytokine production (TNF-α (a), interferon-γ (b), IL-8 (c), IL-10 (d)) by peripheral blood mononuclear cells (PBMC) stimulated with faecal samples from healthy volunteers before and after the gluten-free diet (GFD) and controls (non-stimulated PBMC). Results are expressed as means of duplicate measures determined in four independent experiments, with standard deviations represented by vertical bars. Statistically significant differences were established by applying Student's *t* test at $P<0.050$. RPMI, Roswell Park Memorial Institute medium. Mean value was significantly different from that before the GFD: * $P<0.037$, ** $P<0.021$, *** $P<0.007$, **** $P<0.002$.

TNF-α and IFN-γ[31]. Therefore, it could be expected that reductions in Th1-type cytokine production were accompanied by increases in the Th2-type and regulatory cytokine IL-10. However, when a stimulus increases IFN-γ production, IL-10 production can also be increased by counter-regulatory mechanisms and vice versa. In this case, it seems likely that GFD led to a generalised reduction of bacterial-induced cytokine production in vitro as a result of the generalised reduction caused by this dietary intervention in the total luminal bacterial load of the large intestine. Moreover, specific bacterial group changes could also be partially responsible for the differences detected in cytokine induction since, for instance, Bifidobacterium genus and particularly some B. longum strains have been acknowledged for their ability to stimulate IL-10 production[25] and their levels were significantly reduced after the GFD. The immune-suppressive effects associated with the GFD may be partly beneficial for CD patients, which are prone to a Th1-biased immune response, but may also imply a defect of their defence and regulatory mechanisms against harmful antigens and chronic inflammation.

Conclusions

The obtained results suggest that a GFD may influence the composition and immune function of the gut microbiota in healthy individuals, without the influence of any underlying disease, parallel with reductions in polysaccharide intake. Although this is a preliminary short-term intervention study, bacterial changes are similar to those detected previously in children after compliance with a long-term GFD. As intestinal bacteria constitute a constant challenge of antigens to their host that modulate immunity, the GFD should be considered as a possible environmental factor that may shape the microbiota composition and gut health in treated CD patients.

References

1. Marsh MN (1992) Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). Gastroenterology 102, 330–354.
2. Sollid LM (2002) Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2, 647–655.
3. Gianfrani C, Auricchio S & Troncone R (2005) Adaptive and innate immune responses in celiac disease. Immunol Lett 99, 141–145.
4. Cinova J, Palová-Jelínková L, Smythies LE, et al. (2007) Gliadin peptides activate blood monocytes from patients with celiac disease. J Clin Immunol 27, 201–209.
5. Cosnes J, Cellier C, Viola S, et al. (2008) Incidence of autoimmune diseases in celiac disease: protective effect of the gluten-free diet. Clin Gastroenterol Hepatol 6, 753–758.
6. Malandrino N, Capristo E, Farnetti S, et al. (2008) Metabolic and nutritional features in adult celiac patients. Dig Dis 26, 128–133.
7. Nadal I, Donat E, Ribes-Koninckx C, et al. (2007) Imbalance in the composition of the duodenal microbiota of children with coeliac disease. J Med Microbiol 56, 1669–1674.
8. Sanz Y, Sánchez E, De Palma G, et al. (2008) Indigenous gut microbiota, probiotics, and coeliac disease. In Child Nutrition and Physiology, pp. 210–224 [LT Overton and MR Ewente, editors]. Hauppauge, NY: Nova Science Publishers.
9. Elder JH, Shankar M, Shuster J, et al. (2006) The gluten-free, casein-free diet in autism: results of a preliminary double blind clinical trial. J Autism Dev Disord 36, 413–420.
10. Farran A, Zamora R & Cervera P (2004) Tablas de Composición de Alimentos CESNID (CESNID Food Composition Tables), 2nd ed. Barcelona: McGraw-Hill/Interamericana.
11. Collado MC, Calabuig M & Sanz Y (2007) Differences between the fecal microbiota of coeliac infants and healthy controls. Curr Issues Intest Microbiol 8, 9–14.
12. Amann RI, Binder BJ, Olson RJ, et al. (1990) Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations. Appl Environ Microbiol 56, 1919–1925.
13. Harmsen HJM, Wildeboer-Veloo AC, Grijpstra J, et al. (2000) Development of 16S rRNA based probes for the Coriobacterium group and the Atopobium cluster and their application for enumeration of Coriobacteriaceae in human feces from volunteers of different age. Appl Environ Microbiol 66, 4523–4527.
14. Langendijk PS, Schut F, Jansen GJ, et al. (1995) Quantitative fluorescence in situ hybridization of Bifidobacterium spp. with genus specific 16S rRNA-targeted probes and its application in fecal samples. Appl Environ Microbiol 61, 3069–3075.
15. Harmsen HJH, Gibson GR, Elfferich P, et al. (1999) Comparison of viable cell counts and fluorescence in situ hybridization using specific rRNA-based probes for the quantification of human fecal bacteria. FEMS Microbiol Lett 183, 125–129.
16. Manz W, Amann R, Ludwig W, et al. (1996) Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum Cytophaga-flavobacter-bacteroides in the natural environment. Microbiology 142, 1097–1106.
17. Poulsen LK, Lan F, Kristensen CS, et al. (1994) Spatial distribution of Escherichia coli in the mouse large intestine inferred from rRNA in situ hybridization. Infect Immun 62, 5191–5194.
18. Franks AH, Harmsen HJM, Raangs GC, et al. (1998) Variations of bacterial populations in human faeces measured by fluorescent in situ hybridization with group specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol 64, 3336–3345.
19. Hold GL, Schwiertz A, Aminov RI, et al. (2003) Oligonucleotide probes that detect quantitatively significant groups of butyrate-producing bacteria in human feces. Appl Environ Microbiol 69, 4320–4324.
20. Suau A, Rochet V, Sghir A, et al. (2001) Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst Appl Microbiol 24, 139–145.
21. Wallner G, Amann R & Beisker W (1993) Optimizing fluorescent in situ hybridization with rRNA-targeted oligonucleotide probes for flow cytometric identification of microorganisms. Cytometry 14, 136–143.
22. Collado MC & Sanz Y (2007) Quantification of mucosa-adhered microbiota of lambs and calves by the use of culture

methods and fluorescent *in situ* hybridization coupled with flow cytometry techniques. *Vet Microbiol* **121**, 299–306.

23. Matsuki T, Watanabe K, Fujimoto J, *et al.* (2002) Development of 16S rRNA-gene-targeted group-specific primers for the detection and identification of predominant bacteria in human feces. *Appl Environ Microbiol* **68**, 5445–5451.

24. Malinen E, Kassinen A, Rinttilä T, *et al.* (2003) Comparison of real-time PCR with SYBR Green I or 5′-nuclease assays and dot-blot hybridization with rDNA-targeted oligonucleotide probes in quantification of selected faecal bacteria. *Microbiology* **149**, 269–277.

25. Medina M, Izquierdo E, Ennahar S, *et al.* (2007) Differential immunomodulatory properties of *Bifidobacterium longum* strains: relevance to probiotic selection and clinical applications. *Clin Exp Immunol* **150**, 531–538.

26. Kinsey L, Burden ST & Bannerman E (2008) A dietary survey to determine if patients with coeliac disease are meeting current healthy eating guidelines and how their diet compares to that of the British general population. *Eur J Clin Nutr* **62**, 1333–1342.

27. De Graaf AA & Venema K (2008) Gaining insight into microbial physiology in the large intestine: a special role for stable isotopes. *Adv Microb Physiol* **53**, 73–168.

28. Collado MC, Donat E, Ribes-Koninckx C, *et al.* (2009) Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. *J Clin Pathol* **62**, 264–269.

29. Swidsinski A, Loening-Baucke V, Vaneechoutte M, *et al.* (2007) Active Crohn's disease and ulcerative colitis can be specifically diagnosed and monitored based on the biostructure of the fecal flora. *Inflamm Bowel Dis* **14**, 147–161.

30. Schell MA, Karmirantzou M, Snel B, *et al.* (2002) The genome sequence of *Bifidobacterium longum* reflects its adaptation to the human gastrointestinal tract. *Proc Natl Acad Sci U S A* **99**, 14422–14427.

31. Mosmann TR (1994) Properties and functions of interleukin-10. *Adv Immunol* **56**, 1–26.